JCO-话题@MedSci

#JCO#

724篇内容 | 6918人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1891619, encodeId=777d189161901, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：18F-FDG–PET/CT定义多发性骨髓瘤代谢完全缓解的标准, objectType=article, longId=203008, objectId=53e32030088f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53e32030088f, replyNumber=0, likeNumber=69, createdTime=2021-07-25, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53e32030088f, moduleTitle=JCO：18F-FDG–PET/CT定义多发性骨髓瘤代谢完全缓解的标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53e32030088f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891622, encodeId=84021891622f0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, objectType=article, longId=204599, objectId=0719204599a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0719204599a7, replyNumber=0, likeNumber=68, createdTime=2021-08-27, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0719204599a7, moduleTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0719204599a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891621, encodeId=fb9918916215a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：为什么乳腺癌的四种复发风险预测分析结果不一样？, objectType=article, longId=203321, objectId=891820332169, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=891820332169, replyNumber=0, likeNumber=109, createdTime=2020-12-30, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=891820332169, moduleTitle=JCO：为什么乳腺癌的四种复发风险预测分析结果不一样？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=891820332169)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891627, encodeId=0fb1189162e5b, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO || 复发性或持续性卵巢癌：纳武利尤单抗联合伊匹单抗的缓解率高, objectType=article, longId=206079, objectId=feef2060e9a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feef2060e9a2, replyNumber=0, likeNumber=88, createdTime=2021-05-16, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feef2060e9a2, moduleTitle=JCO || 复发性或持续性卵巢癌：纳武利尤单抗联合伊匹单抗的缓解率高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feef2060e9a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891636, encodeId=1b7b189163601, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：转移性精原细胞瘤的存活率和新不良预后因素, objectType=article, longId=208650, objectId=f18620865031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f18620865031, replyNumber=0, likeNumber=68, createdTime=2021-11-18, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f18620865031, moduleTitle=JCO：转移性精原细胞瘤的存活率和新不良预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f18620865031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891617, encodeId=7793189161e06, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：西妥昔单抗联合放疗治疗晚期头颈部鳞状细胞癌疗效次于顺铂, objectType=article, longId=202297, objectId=bcfe20229e68, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcfe20229e68, replyNumber=0, likeNumber=80, createdTime=2021-03-12, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcfe20229e68, moduleTitle=JCO：西妥昔单抗联合放疗治疗晚期头颈部鳞状细胞癌疗效次于顺铂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcfe20229e68)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891613, encodeId=15c4189161328, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：肿瘤沉积可能降低Ⅲ期结肠癌的无病生存率, objectType=article, longId=192311, objectId=e0d0192311da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0d0192311da, replyNumber=0, likeNumber=66, createdTime=2020-11-22, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0d0192311da, moduleTitle=JCO：肿瘤沉积可能降低Ⅲ期结肠癌的无病生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0d0192311da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891620, encodeId=08ba189162097, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率, objectType=article, longId=203319, objectId=209120331967, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=209120331967, replyNumber=0, likeNumber=80, createdTime=2020-12-16, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=209120331967, moduleTitle=JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=209120331967)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891610, encodeId=8fb418916102f, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=189823, objectId=597d18982326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597d18982326, replyNumber=0, likeNumber=65, createdTime=2020-08-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597d18982326, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597d18982326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891608, encodeId=f56f189160876, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, objectType=article, longId=183247, objectId=74bf18324ece, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bf18324ece, replyNumber=0, likeNumber=82, createdTime=2020-06-29, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bf18324ece, moduleTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74bf18324ece)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891615, encodeId=9528189161578, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：肥胖又耽误事儿！大型回顾性分析表明，肥胖乳腺癌患者化疗效果差！, objectType=article, longId=197120, objectId=6af619e120e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6af619e120e1, replyNumber=0, likeNumber=0, createdTime=2020-11-10, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6af619e120e1, moduleTitle=JCO：肥胖又耽误事儿！大型回顾性分析表明，肥胖乳腺癌患者化疗效果差！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6af619e120e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891605, encodeId=1330189160532, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：结直肠癌患者坚持健身或能缓解病情, objectType=article, longId=180283, objectId=303218028350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=303218028350, replyNumber=0, likeNumber=0, createdTime=2020-04-16, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=303218028350, moduleTitle=JCO：结直肠癌患者坚持健身或能缓解病情, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=303218028350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891614, encodeId=feb81891614fe, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, objectType=article, longId=194692, objectId=93bf194692fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93bf194692fc, replyNumber=0, likeNumber=131, createdTime=2021-04-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93bf194692fc, moduleTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93bf194692fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891606, encodeId=5c9c18916064a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO Clin Cancer Inform：真实世界证据，用在哪？如何用？看看FDA试点研究结果怎么说, objectType=article, longId=180640, objectId=9c7c1806407e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c7c1806407e, replyNumber=0, likeNumber=52, createdTime=2019-11-20, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c7c1806407e, moduleTitle=JCO Clin Cancer Inform：真实世界证据，用在哪？如何用？看看FDA试点研究结果怎么说, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c7c1806407e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891597, encodeId=b1c6189159ea6, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：依鲁替尼和Venetoclax连用，可治疗复发/难治性慢性淋巴细胞白血病, objectType=article, longId=175433, objectId=30531e5433ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30531e5433ab, replyNumber=0, likeNumber=61, createdTime=2019-10-29, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30531e5433ab, moduleTitle=JCO：依鲁替尼和Venetoclax连用，可治疗复发/难治性慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30531e5433ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891612, encodeId=7e921891612b7, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：三阴性乳腺癌治疗“中国方案”全球首发，患者5年无病生存率提升6%（CBCSG010研究）, objectType=article, longId=192030, objectId=e87b192030fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e87b192030fa, replyNumber=0, likeNumber=83, createdTime=2020-12-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e87b192030fa, moduleTitle=JCO：三阴性乳腺癌治疗“中国方案”全球首发，患者5年无病生存率提升6%（CBCSG010研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e87b192030fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891591, encodeId=2e90189159197, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=J Clin Oncol:局部晚期肺癌新希望——JCO发表CTONG 1103靶向-手术-靶向多中心研究成果, objectType=article, longId=168698, objectId=ca0c168698eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0c168698eb, replyNumber=0, likeNumber=66, createdTime=2019-12-01, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0c168698eb, moduleTitle=J Clin Oncol:局部晚期肺癌新希望——JCO发表CTONG 1103靶向-手术-靶向多中心研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0c168698eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891611, encodeId=6de01891611c2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, objectType=article, longId=190106, objectId=ce37190106a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce37190106a8, replyNumber=0, likeNumber=75, createdTime=2020-06-10, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce37190106a8, moduleTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce37190106a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891590, encodeId=18f2189159031, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：小儿脑肿瘤患者耳毒性的认知意义, objectType=article, longId=165948, objectId=771d1659487d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=771d1659487d, replyNumber=0, likeNumber=87, createdTime=2020-03-19, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=771d1659487d, moduleTitle=JCO：小儿脑肿瘤患者耳毒性的认知意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=771d1659487d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891609, encodeId=81461891609f5, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：75万人大型前瞻性队列研究发现，锻炼可降低七种癌症风险!, objectType=article, longId=185427, objectId=ccf918542e78, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccf918542e78, replyNumber=0, likeNumber=89, createdTime=2020-10-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccf918542e78, moduleTitle=JCO：75万人大型前瞻性队列研究发现，锻炼可降低七种癌症风险!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccf918542e78)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JCO

2020-05-29

docwu2019 (审核中...)

前往app查看评论内容

#JCO#

JCO：18F-FDG–PET/CT定义多发性骨髓瘤代谢完全缓解的标准

2021-07-25

爆笑小医 (审核中...)

前往app查看评论内容

#JCO#

JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用

2021-08-27

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：为什么乳腺癌的四种复发风险预测分析结果不一样？

2020-12-30

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO || 复发性或持续性卵巢癌：纳武利尤单抗联合伊匹单抗的缓解率高

2021-05-16

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：转移性精原细胞瘤的存活率和新不良预后因素

2021-11-18

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：西妥昔单抗联合放疗治疗晚期头颈部鳞状细胞癌疗效次于顺铂

2021-03-12

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：肿瘤沉积可能降低Ⅲ期结肠癌的无病生存率

2020-11-22

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：rhG-CSF联合小剂量地西他滨可降低HR-AML患者allo-HSCT后的复发率

2020-12-16

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2020-08-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164

2020-06-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：肥胖又耽误事儿！大型回顾性分析表明，肥胖乳腺癌患者化疗效果差！

2020-11-10

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：结直肠癌患者坚持健身或能缓解病情

2020-04-16

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致

2021-04-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO Clin Cancer Inform：真实世界证据，用在哪？如何用？看看FDA试点研究结果怎么说

2019-11-20

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：依鲁替尼和Venetoclax连用，可治疗复发/难治性慢性淋巴细胞白血病

2019-10-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：三阴性乳腺癌治疗“中国方案”全球首发，患者5年无病生存率提升6%（CBCSG010研究）

2020-12-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

J Clin Oncol:局部晚期肺癌新希望——JCO发表CTONG 1103靶向-手术-靶向多中心研究成果

2019-12-01

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后

2020-06-10

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：小儿脑肿瘤患者耳毒性的认知意义

2020-03-19

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：75万人大型前瞻性队列研究发现，锻炼可降低七种癌症风险!

2020-10-04

科室
- - 订阅+
  - 更多科室
工具
服务